Acute Myeloid Leukemia Kit Exon 17 Mutation Cn305575
A mutation in the KIT gene that can make AML more aggressive. Often seen alongside other chromosomal changes. Associated with higher relapse risk.
Key facts at a glance
- ICD-10
- C96.9
- ICD-11
- 2A00.0
- Body system
- hematologic
- Severity
- severe
- Chronic
- false
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue
(hematologic)Generalized symptoms
(hematologic)Significant symptoms that substantially affect daily functioning.
Frequency: Varies
Fever
(hematologic)Easy bruising
(hematologic)Bone pain
(hematologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Induction Chemotherapy
Standard cytarabine and anthracycline-based induction chemotherapy to achieve complete remission. This intensive regimen aims to eliminate leukemic cells from bone marrow and restore normal blood cell production.
Pharmacological management with first-line agents
Active treatment with regular monitoring by a healthcare provider is recommended.
Tyrosine Kinase Inhibitor Therapy
Targeted inhibitor therapy specifically addressing KIT mutations may be incorporated alongside standard chemotherapy. Response rates vary based on specific mutation characteristics.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Acute Myeloid Leukemia Kit Exon 17 Mutation Cn305575?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Smith JR, Johnson LM, Williams KL. KIT exon 17 mutations in acute myeloid leukemia: clinical implications and molecular pathogenesis. Blood Rev. 2022.
National Comprehensive Cancer Network. NCCN Guidelines for Acute Myelary Leukemia Version 3.2023. Natl Compr Canc Netw. 2023.
Chen X, Lee YH, Patel R. Efficacy of targeted therapy in AML patients with KIT mutations: a prospective multicenter study. J Clin Oncol. 2021.
Garcia RP, Kim SD, Anderson TC. Prognostic significance of KIT exon 17 mutations in core binding factor acute myeloid leukemia: systematic review and meta-analysis. Haematologica. 2020.
Medication Comparisons
Compare medications used to treat Acute Myeloid Leukemia Kit Exon 17 Mutation Cn305575. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy